A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Global Crossing Airlines Group, Inc. is a US 121 domestic flag and supplemental Airline flying the Airbus A320 family aircraft. GlobalX flies as a passenger ACMI and charter airline serving the US, Caribbean, European and Latin American markets. This company webcast...
Mitch Pinheiro, Sturdivant & Co., takes a timely look at the food space — from the rising cost of healthy eating to the effects of inflation, tariffs, and shifting consumer habits. Learn how companies and investors can navigate this evolving landscape. This Panel was...
Celebrated Public Listing by Ringing the Opening Bell Today at the Nasdaq Stock Exchange SINGAPORE, June 27, 2025 /PRNewswire/ -- Hotel101 Global Holdings Corp. ("Hotel101" or "HBNB"), an asset-light, prop-tech hospitality platform business designed for rapid global...
Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+...
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief...
This company webcast features Haypp Group AB. Haypp Group (SEK: HAYPP) is leading the transition from smoking to smoke-free alternatives. This company webcast was recorded during the Lytham Partners Spring 2025 Investor Conference.
Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. LOS ANGELES - Niagen...
Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion LOS ANGELES - Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex...
Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global...
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at...